177 filings
Page 5 of 9
6-K
MDNAF
Medicenna Therapeutics Corp.
8 Sep 22
Medicenna to Present at Investor and Scientific Conferences in September
5:19pm
6-K
MDNAF
Medicenna Therapeutics Corp.
22 Aug 22
Current report (foreign)
11:39am
6-K
MDNAF
Medicenna Therapeutics Corp.
22 Aug 22
Form 51-102F3 Material Change Report
9:59am
6-K
MDNAF
Medicenna Therapeutics Corp.
15 Aug 22
Interim Condensed Consolidated Statements of Financial Position
8:00am
6-K
MDNAF
Medicenna Therapeutics Corp.
11 Aug 22
Medicenna Announces Closing of Public Offering of Units
4:36pm
6-K
MDNAF
Medicenna Therapeutics Corp.
11 Aug 22
Current report (foreign)
12:53pm
SUPPL
MDNAF
Medicenna Therapeutics Corp.
10 Aug 22
Supplemental materials (foreign)
3:10pm
6-K
MDNAF
Medicenna Therapeutics Corp.
9 Aug 22
Medicenna Announces the Launch of a Marketed Underwritten Public Offering of Units
9:22am
SUPPL
MDNAF
Medicenna Therapeutics Corp.
9 Aug 22
Supplemental materials (foreign)
12:00am
6-K
MDNAF
Medicenna Therapeutics Corp.
9 Aug 22
Medicenna Announces Pricing of US$20 Million Public Offering of Units
12:00am
SUPPL
MDNAF
Medicenna Therapeutics Corp.
8 Aug 22
Supplemental materials (foreign)
8:40pm
6-K
MDNAF
Medicenna Therapeutics Corp.
5 Aug 22
Current report (foreign)
7:59am
6-K
MDNAF
Medicenna Therapeutics Corp.
27 Jul 22
Medicenna Announces New Clinical Data Providing Preliminary Evidence of MDNA11’s Single Agent Anti-Cancer Activity in the Phase 1/2 ABILITY Study
8:06am
20-F
2022 FY
MDNAF
Medicenna Therapeutics Corp.
22 Jun 22
Annual report (foreign)
5:04pm
6-K
MDNAF
Medicenna Therapeutics Corp.
22 Jun 22
Current report (foreign)
8:00am
6-K
MDNAF
Medicenna Therapeutics Corp.
22 Jun 22
Medicenna Reports Fiscal Year 2022 Financial Results and Operational Highlights
7:15am
6-K
MDNAF
Medicenna Therapeutics Corp.
9 Jun 22
Medicenna Strengthens Intellectual Property Protection for Superkine Platform with Issuance of U.S. Patent
7:39am
6-K
MDNAF
Medicenna Therapeutics Corp.
7 Jun 22
Current report (foreign)
9:12am
6-K
MDNAF
Medicenna Therapeutics Corp.
11 May 22
Current report (foreign)
8:24am
6-K
MDNAF
Medicenna Therapeutics Corp.
2 May 22
Medicenna Announces New Clinical Data Showing Dose-Dependent Stimulation of Anti-Cancer Immune Cells with MDNA11 in the Phase 1/2 ABILITY Study
8:15am